Clinical Trial

Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 9, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Concurrent chemoradiotherapy (cCRT) is the standard treatment for patients with negative epidermal growth factor receptor (EGFR)-mutated unresectable locally advanced non-small cell lung cancer (LA-NSCLC). However, parts of patients only receive sequential chemoradiotherapy (sCRT) due to various reasons. This phase II study aimed to improve the outcomes of patients receiving sCRT by combining anti-angiogenesis therapy (Anlotinib) during radiotherapy course.We hypothesize that the combination of radiotherapy with anlotinib could improve the 2-year PFS rate from 35% with sCRT to 50. The accrual target was 44 patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-23.
Trial Details
NCT Number NCT07037680
Lead Sponsor JIANYANG WANG
Conditions Locally Advanced Non-Small Cell Lung Cancer, Thoracic Radiotherapy, Safety
Enrollment 44 participants
Start Date 2024-01-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-09